rinucumab + aflibercept

**Rinucumab + aflibercept** is an experimental intravitreal combination therapy developed as a single coformulated injection for the treatment of neovascular (wet) age-related macular degeneration (AMD). It combines **rinucumab**, a fully human monoclonal antibody inhibitor of platelet-derived growth factor receptor beta (PDGFRβ), with **aflibercept**, a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor A (VEGF-A), VEGF-B, and placental growth factor (PlGF). By targeting both **PDGFRβ** and **VEGF** pathways, the combination was hypothesized to enhance antiangiogenic efficacy and decrease fibrosis by disrupting both vessel formation and pericyte stabilization in choroidal neovascularization. Clinical trials (including CAPELLA and REGN2176-3) found that the combination did not provide additional visual or anatomic benefit over aflibercept monotherapy, and development was discontinued for wet AMD due to lack of efficacy and increased adverse ocular events[1][3][5][7][9].

Other names

aflibercept/rinucumabrinucumab/EyleaPDGFR-beta-Eylea combination therapy